Home › Companies › VRCA

Verrica Pharmaceuticals

Market cap $53.9M 17.2M shares (10-Q, Nov 5, 2026) × $3.14 close Nov 17, 2026

Most recent annual filing: 2026-03-11

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. YCANTH commercial units corporate updateNov 2026YCANTH commercial units corporate update, Nov 2026, routine
  2. YCANTH (VP-102) common warts toplinemid-2027YCANTH (VP-102) common warts topline, mid-2027, thesis-defining
  3. Verrica financingJun 2027Verrica financing, Jun 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$14.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$9.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$14.4M cash, runway into the fourth quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Verrica Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Verrica Pharmaceuticals (VRCA) — Scientific Deep Dive for YCANTH, VP-102 in Common Warts, and VP-315 Going-concern balance sheet cannot reach its own mid-2027 catalyst on committed capital, and the Chairman holds a first lien plus a 16% IRR catch-up that triggers on commercial success, keeping the stock on the sidelines until the delayed draw unlocks or a signed partnership funds the gap.
  2. Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Catalyst Moved to the Money COVE-2 enrollment completion pulled the topline into Q1 2027, inside the committed-capital window, eliminating the timing mismatch that was the load-bearing beam of the bear case and warranting a small starter position sized for total loss.
  3. Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Delayed Draw Unlocks The full $27.5M facility is now available after Verrica met the lender's milestones, funding both COVE pivotal readouts without a dilutive raise, satisfying the first of the two conditions set in the deep dive for moving off the sidelines.
  4. Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Price Turned, the Units Blinked Q3 per-applicator revenue rebounded to ~$298, burn held near $9.3M/quarter, and the delayed draw is unlocked, passing all three hard-review checks, though a sequential unit dip and shortened runway guidance are flagged as risks to monitor into COVE-2.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (5 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (19)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)